Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity
93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process
…
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Share this article
More News
3 Growth Stocks to Stash
June 9, 2026
IBM Stock Analysis: Buy or Sell?
June 9, 2026
What’s Behind The Price Momentum?
June 9, 2026